新聞/Reuters/Takeda Pharmaceutical - Positive Results From Two Pivotal Phase 3 Studies Of Oveporexton (Tak-861) In Narcolepsy Type 1Takeda Pharmaceutical - Positive Results From Two Pivotal Phase 3 Studies Of Oveporexton (Tak-861) In Narcolepsy Type 1Refinitiv閱讀少於1分鐘4502Takeda Pharmaceutical Co Ltd 4502:ANNOUNCES POSITIVE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF OVEPOREXTON (TAK-861) IN NARCOLEPSY TYPE 1Reuters亞洲日本股票© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html顯示更多登入或建立一個永久免費帳戶來閱讀此新聞讓我們開始吧
